| Patented Medicine Prices Review Board Canada
| news releases
A new Patented Medicine Prices Review Board (PMPRB) report reveals that prescription drug expenditures by Canadian public drug plans reached $11.3 billion in 2015-16, up $1 billion over the previous year. This increase was mainly driven by a 12% growth in drug costs. While new and curative treatments for hepatitis C were major contributors to this growth, other high-cost drugs continued to put upward pressure on drug plans.
| Patented Medicine Prices Review Board Canada
| statements
Patented Medicine Prices Review Board (PMPRB) Vice-chairperson Dr. Mitchell Levine today made the following statement on the launch of Health Canada’s consultation on potential changes to the Patented Medicines Regulations:
| Patented Medicine Prices Review Board Canada
| news releases
Closing arguments in the matter of the price of the patented medicine Soliris will be heard from Patented Medicine Prices Review Board staff, Alexion Pharmaceuticals Inc., and the intervenor, BIOTECanada, on Tuesday, April 18 and Wednesday, April 19, 2017, from 9:00 a.m. to 4:30 p.m. (EST).
| Patented Medicine Prices Review Board Canada
| news releases
The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, today published the first edition of Meds Entry Watch, a new annual publication that provides information on recently launched drugs in Canada and select international markets. This report series is designed to inform decision makers, researchers, and patients of the evolving market dynamics of emerging drug therapies.
| Patented Medicine Prices Review Board Canada
| news releases
The Patented Medicine Prices Review Board (PMPRB) is seeking applicants for membership on the Board by way of open, transparent, and merit-based Governor in Council selection processes for the positions of Chairperson and Board member.
| Patented Medicine Prices Review Board Canada
| news releases
The Patented Medicine Prices Review Board (the Board) will hold a public hearing in the matter of the price of the patented medicine Soliris and Alexion Pharmaceuticals Inc. (Alexion), the pharmaceutical company that exercises patent rights for Soliris and sells the medicine in Canada.
| Patented Medicine Prices Review Board Canada
| news releases
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on December 19, 2016 relating to the medicines Differin and Differin XP, manufactured and marketed in Canada by Galderma Canada Inc. (Galderma).
| Patented Medicine Prices Review Board Canada
| news releases
The Patented Medicine Prices Review Board (PMPRB) is pleased to announce the reappointment of Dr. Mitchell Levine of Hamilton, Ontario as Vice-chairperson of the Board for a second five-year term.
| Patented Medicine Prices Review Board Canada
| news releases
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued an Order on October 28, 2016 requiring that Baxalta Canada Corporation (Baxalta) provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations.
